Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05809362 · ClinicalTrials.gov registry record
WHOOP Abnormal Rhythm Notification
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 653
- Enrollment target
NCT05809362: Completed study, sponsored by Yale University.
NCT05809362 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 653 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05809362 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 653 participants
- Enrollment target
Study Summary
The purpose of this protocol is to assess the sensitivity and specificity of a photoplethysmography (PPG)-based algorithm for the detection of atrial fibrillation as compared to a gold-standard assessment (wearable ECG patch) among a population of individuals with known atrial fibrillation and without known atrial fibrillation over a 7-day study period.
Primary Outcome
Sensitivity is defined as the True Positives/(True Positives + False Negatives). A "true" atrial fibrillation reading will have an ECG patch reading consistent with sustained atrial fibrillation for at least 5 continuous minutes. A WHOOP ANF diagnosis of atrial fibrillation is defined as "atrial fibrillations" being detected using the internal algorithm. A true positive is defined as the count of individuals who have at least 1 window labelled as Afib by WHOOP ANF and which has 5+ minutes of con
Interventions
- DEVICE WHOOP 4.0 Strap
- DEVICE BioTel ePatch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 653 participants |
| Start Date | 2023-04-10 |
| Est. Completion | 2024-01-25 |
What the finished NCT05809362 record still lists
NCT05809362 is an observational study that tracks outcomes without assigning an intervention. The registered 653 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which WHOOP 4.0 Strap is the first listed.
NCT05809362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05809362 about?
NCT05809362 is a clinical study titled "WHOOP Abnormal Rhythm Notification". The purpose of this protocol is to assess the sensitivity and specificity of a photoplethysmography (PPG)-based algorithm for the detection of atrial fibrillation as compared to a gold-standard assessment (wearable ECG patch) among a population of individuals with known atrial fibrillation and witho...
What is the current status of trial NCT05809362?
This trial is currently completed. The enrollment target is 653 participants. The study started on 2023-04-10. Estimated completion is 2024-01-25.
What interventions are being tested in trial NCT05809362?
The interventions under investigation include: WHOOP 4.0 Strap (DEVICE), BioTel ePatch (DEVICE).
Who is sponsoring clinical trial NCT05809362?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06287346 · 652 participants
5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.
- NCT07145515 · 655 participants · NA
Enhancing Heart Allograft Function With the OCS Heart System Trial
- NCT05407129 · 656 participants · NA
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
- NCT06127199 · 656 participants · NA
Contraceptive Efficacy Study of Ovaprene
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI